Youth Vaping Is "Predictable" by Design - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Youth Vaping Is "Predictable" by Design

Product engineering, not individual choice, is driving adolescent nicotine dependence, researchers argue.

  • By

  • Kerri Miller

  • June 5, 2026

  • 3 min

Share

Clinical Scorecard: Youth Vaping Is 'Predictable' by Design

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdolescents aged 13 to 15 years
Care Setting

Key Highlights

  • Vaping prevalence among adolescents is nine times that of adults.
  • E-cigarette products with at least 5% nicotine strength increased by 1,486% from 2017 to 2022.
  • Evidence of harms in youth includes addiction, toxicity, and increased smoking uptake.
  • Long-term effects of e-cigarettes on clinical outcomes remain uncertain.

Guideline-Based Recommendations

Diagnosis

  • Recognize nicotine dependence in adolescents as influenced by product design and marketing.

Management

  • Implement pre-market safety standards and retailer licensing reform.

Monitoring & Follow-up

  • Monitor youth exposure to e-cigarettes and related health outcomes.

Risks

  • Acknowledge risks of addiction, toxicity, and other health harms associated with vaping.

Patient & Prescribing Data

Adolescents at risk of nicotine dependence due to vaping.

Focus on addressing upstream factors such as product design and marketing.

Clinical Best Practices

  • Incorporate discussions of product design and commercial systems in counseling.
  • Advocate for flavor restrictions and comprehensive tobacco control measures.

Related Resources & Content

Original Source(s)

Youth Vaping Is "Predictable" by Design

  • by Kerri Miller

  • June 5, 2026

Related Content

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

NEJM Retracts Avacopan Vasculitis Study

"The primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding"